A so-called "natural Mounjaro" drink has gone viral online thanks to claims it can lead to significant weight loss. Here's ...

The weight-loss succession race is heating up. Here's how biopharma execs talked up those efforts at JPM this week.

Pharmacy professor Nicole Albanese discusses the science behind drugs like Ozempic and Wegovy, their potential to treat other ...

JPM25 is in full swing as several pharma powerhouses—including Merck, Lilly and Amgen—detail their strategies for growth in ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

Commenting on the commission, Dr Kath McCullough, special adviser on obesity at the Royal College of Physicians, said: “For too long, we’ve relied on BMI as a simple measure of obesity, which has ...

The series A fundraising is the biggest ever for a European biotech firm, according to the data provider PitchBook.

For the first time in over a decade, obesity rates have dropped in the United States. A recent study by the CDC showed that from 2021 to 2023, those rates dropped from 41.9% to 40.3%.

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.

Up to 3.4 million eligible patients could benefit from the medication that treats type 2 diabetes and aids weight loss ...

Eli Lilly expects 2024 revenue of $45.0 billion, reflecting a 32% increase, with strong contributions from Mounjaro and ...

The proportion of obese Indians has risen from 25 per cent in 2013 to 40 per cent in 2023, highlighting the need for ...